A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions
Chronic Lymphocytic Leukemia · Lymphoma, Small Lymphocytic
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mitchell Cancer Institute, Mobile, Alabama, United States
Contact: Principal Investigator (Anita Mazloom)Arizona Oncology Associates, P.C. - HOPE, Tucson, Arizona, United States
Contact: Principal Investigator (Sudhir Manda)Cancer Specialists, LLC, Jacksonville, Florida, United States
Contact: Principal Investigator (Ayed Ayed)Minnesota Oncology Hematology, P.A., Coon Rapids, Minnesota, United States
Contact: Principal Investigator (Avina Singh)Cayuga Cancer Center, Ithaca, New York, United States
Contact: Principal Investigator (Cynthia Davis)Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York, United States
Contact: Principal Investigator (Prioty Islam)Oncology Hematology Care Inc, Cincinnati, Ohio, United States
Contact: Principal Investigator (Kruti Patel)Texas Oncology - Paris, Fort Worth, Texas, United States
Contact: Principal Investigator (Harris Naina)US Oncology - Texas Oncology, Kyle, Texas, United States
Contact: Principal Investigator (David Friedman)The Alfred Hospital, Melbourne, Australia
Contact: Principal Investigator (Constantine Tam)LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria
Contact: Principal Investigator (Alexander Egle)AZ Delta, Roeselare, Belgium
Contact: Principal Investigator (Lien Deleu)Princess Margaret Cancer Centre - University Health Network, Toronto, Canada
Contact: Principal Investigator (Christine Chen)Xuanwu Hospital Capital Medical University, Beijing, China
Contact: Principal Investigator (Wuhan Hui)Hunan Cancer Hospital, Changsha, China
Contact: Principal Investigator (Hui Zhou)Sun Yat-sen University Cancer Center, Guangdong, China
Contact: Principal Investigator (He Huang)Nanfang Hospital of Southern Medical University, Guangzhou, China
Contact: Principal Investigator (RU FENG)Gansu Provincial Cancer Hospital, Lanzhou, China
Contact: Principal Investigator (Jie Cui)The First Affiliated Hospital of Nanchang University, Nanchang, China
Contact: Principal Investigator (Fei Li)Fudan University Shanghai Cancer Center, Shanghai, China
Contact: Principal Investigator (Junning Cao)Taizhou Hospital of Zhejiang Province, Taizhou, China
Contact: Principal Investigator (Qunyi Guo)Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, China
Contact: Principal Investigator (Rui Lv)Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
Contact: Principal Investigator (Lihua Qiu)Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi, China
Contact: Principal Investigator (Shune Yang)The Affiliated Hospital of Xuzhou Medical College, Xuzhou, China
Contact: Principal Investigator (Jiang Cao)Henan Cancer Hospital, Zhengzhou, China
Contact: Principal Investigator (Keshu Zhou)University Hospital Center Zagreb, Zagreb, Croatia
Contact: Principal Investigator (Igor Aurer)Fakultni nemocnice Hradec Kralove, Hradec Králové, Czechia
Contact: Principal Investigator (Martin Simkovic)Centre Henri Becquerel, Rouen, France
Contact: Principal Investigator (Stéphane Leprêtre)Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet, Budapest, Hungary
Contact: Principal Investigator (Zoltan Matrai)Debreceni Egyetem, Debrecen, Hungary
Contact: Principal Investigator (Illes Arpad)St. James's Hospital, Dublin, Ireland
Contact: Principal Investigator (Carmel Waldron)Beaumont Hospital, Dublin, Ireland
Contact: Principal Investigator (Philip Murphy)Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Contact: Principal Investigator (Gioacchino Catania)Azienda Ospedaliera Universitaria Careggi, Florence, Italy
Contact: Principal Investigator (alessandro sanna)Presidio Ospedaliero Papardo, Messina, Italy
Contact: Principal Investigator (Donato Mannina)Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
Contact: Principal Investigator (Carlo Gambacorti-Passerini)Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Italy
Contact: Principal Investigator (PAOLO SPORTOLETTI)Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Contact: Principal Investigator (LUCA LAURENTI)Tel Aviv Sourasky Medical Center, Tel Aviv, Italy
Contact: Principal Investigator (Yair Herishanu)Azienda Ospedaliera S. Maria Di Terni, Terni, Italy
Contact: Principal Investigator (Arcangelo Liso)Tokai University Hospital, Isehara, Japan
Contact: Principal Investigator (Yoshiaki Ogawa)Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im.ks.B.Markiewicza, Brzozów, Poland
Contact: Principal Investigator (Jacek Krzanowski)Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy, Bydgoszcz, Poland
Contact: Principal Investigator (Marta Sobas)Pratia Onkologia Katowice, Katowice, Poland
Contact: Principal Investigator (Sebastian Grosicki)Hospital Universitario Marques De Valdecilla, Santander, Spain
Contact: Principal Investigator (LUCRECIA YANEZ SAN SEGUNDO)Hospital Universitario Virgen Del Rocio, Seville, Spain
Contact: Principal Investigator (Fatima de la Cruz Vicente)Castle Hill Hospital, Hull, United Kingdom
Contact: Principal Investigator (David Allsup)St James's University Hospital, Leeds, United Kingdom
Contact: Principal Investigator (Talha Munir)GenesisCare, Newmarket, United Kingdom
Contact: Principal Investigator (George Follows)
Study leads
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company